Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG505 MD39.3 mRNA HIV Vaccines in Healthy Adults
NCT05217641Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA and BG505 MD39.3 gp151 CD4KO mRNA in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness, Number of Participants Reporting Local Unsolicited Adverse Events Signs and Symptoms: Erythema and/or Induration and 6 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
BG505 MD39.3 mRNABG505 MD39.3 gp151 mRNABG505 MD39.3 gp151 CD4KO mRNA
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05217641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217641.